Home › Companies › REATA PHARMACEUTICALS INC. › 2023-2024
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and REATA PHARMACEUTICALS INC.’s Form 8-K, filed September 21, 2023 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of September 21, 2023: 3 items on REATA PHARMACEUTICALS INC.’s Form 8-K, filed September 21, 2023: 3 approved.
Notable dissent: 1 other board item (31.7% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Proxy season: 2023-2024
Explore REATA PHARMACEUTICALS INC. in the interactive database Compare manager voting policies
These tallies are REATA PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed September 21, 2023 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| 1. The Merger Proposal: To approve and adopt the Agreement and Plan of Merger, dated as of July 28, 2023, as such agreement may be amended from time to time (the " Merger Agreement "), by and among Biogen Inc., a Delaware corporation (" Biogen | 41,461,455 | 39,094 | 34,360 | -- | 0 | 99.9% | Approved | — |
| 2. Advisory Compensation Proposal: To approve, on an advisory, non-binding basis, compensation that will or may be paid or become payable to Reata's named executive officers in connection with the Merger contemplated by the Merger Agreemen | 28,023,999 | 12,977,053 | 533,857 | -- | 0 | 68% | Approved | — |
| 3. The Adjournment Proposal: To approve to adjourn the Special Meeting to a later date if necessary and appropriate to solicit additional proxies if there are insufficient votes to adopt the Merger Agreement at the time of the Special Meeting | 40,145,724 | 1,261,433 | 127,752 | -- | 0 | 97% | Approved | — |
Source: REATA PHARMACEUTICALS INC., Form 8-K, filed with the SEC on September 21, 2023 — read the filing on EDGAR.
See voting trends for Health Care companies, 2023-2024: shareholder support by sector and by company size.
263 asset managers disclosed a vote on at least one REATA PHARMACEUTICALS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of REATA PHARMACEUTICALS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 3 wordings of this item as funds reported it.
99.9% Approved · of votes cast
Description as filed by funds: To approve and adopt the Agreement and Plan of Merger, dated as of July 28, 2023, as such agreement may be amended from time to time (the "Merger Agreement"), by and among Biogen Inc., a Delaware corporation ("Biogen"), River Acquisition, Inc., a Delaware corporation and wholly-owned subsidiary of Biogen ("Merger Sub"), and Reata Pharmaceuticals, Inc. ("Reata"), pursuant to which Merger Sub will be merged with and into Reata, with Reata surviving as a wholly-owned subsidiary of Biogen (the "Merger").
REATA PHARMACEUTICALS INC.’s own tally for this item (“1. Proposal No. 1 - The Merger Proposal: To approve and adopt the Agreement and Plan of Merger, dated as of July 28, 2023, as such agreement may be amended from time to time (the " Merger Agreement "), by and among Bioge”): 41,461,455 for, 39,094 against — passed, per its Form 8-K filed September 21, 2023 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Merger Proposal was approved by the requisite vote as follows:”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,777,206 | 0 | 0 | 0 | For |
| BlackRock | 1,131,027 | 0 | 0 | 0 | For |
| Fidelity | 624,911 | 0 | 0 | 0 | For |
| Invesco | 400,289 | 0 | 0 | 0 | For |
| Charles Schwab | 217,992 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 193,478 | 0 | 0 | 0 | For |
| Voya | 191,544 | 0 | 0 | 0 | For |
| MERGER FUND | 189,620 | 0 | 0 | 0 | For |
| New York Life | 167,391 | 0 | 0 | 0 | For |
| ARBITRAGE FUNDS | 150,311 | 0 | 0 | 0 | For |
| NEXPOINT FUNDS I | 148,800 | 0 | 0 | 0 | For |
| FINANCIAL INVESTORS TRUST | 135,440 | 0 | 0 | 0 | For |
| Investment Managers Series Trust II | 99,879 | 0 | 0 | 0 | For |
| State Street | 96,154 | 0 | 0 | 0 | For |
| Principal | 93,645 | 0 | 0 | 0 | For |
| Equitable | 55,180 | 0 | 32,500 | 0 | Mixed |
| Columbia Threadneedle | 80,997 | 0 | 0 | 0 | For |
| TIAA | 79,284 | 0 | 0 | 0 | For |
| Goldman Sachs | 53,965 | 0 | 0 | 0 | For |
| Jackson National | 52,392 | 0 | 0 | 0 | For |
| American Century | 51,846 | 0 | 0 | 0 | For |
| JPMorgan | 50,873 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 49,408 | 0 | 0 | 0 | For |
| ALGER INSTITUTIONAL FUNDS | 38,692 | 0 | 0 | 0 | For |
| Aberdeen | 34,250 | 0 | 0 | 0 | For |
Fund voting reports, all 74 managers: 7,695,081 for, 32,500 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| TimesSquare Capital Management, LLC | 274,468 | 0 | 0 | 0 | For |
| UNITED CAPITAL FINANCIAL ADVISORS, LLC | 49 | 0 | 0 | 0 | For |
Institutional-manager reports, all 2 managers: 274,517 for.
Combines 2 wordings of this item as funds reported it.
97% Approved · of votes cast
Description as filed by funds: To approve to adjourn the Special Meeting to a later date if necessary and appropriate to solicit additional proxies if there are insufficient votes to adopt the Merger Agreement at the time of the Special Meeting.
REATA PHARMACEUTICALS INC.’s own tally for this item (“3. Proposal No. 3 - The Adjournment Proposal: To approve to adjourn the Special Meeting to a later date if necessary and appropriate to solicit additional proxies if there are insufficient votes to adopt the Merger Agree”): 40,145,724 for, 1,261,433 against — passed, per its Form 8-K filed September 21, 2023 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Although the Adjournment Proposal was deemed not necessary because there was a quorum present and there were sufficient proxies at the time of the Special Meeting to approve the Merger Proposal, it was approved by the requisite vote as follows:”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,777,206 | 0 | 0 | 0 | For |
| BlackRock | 1,131,027 | 0 | 0 | 0 | For |
| Fidelity | 47,795 | 577,116 | 0 | 0 | Mixed |
| Invesco | 400,289 | 0 | 0 | 0 | For |
| Charles Schwab | 217,992 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 193,478 | 0 | 0 | 0 | For |
| Voya | 191,544 | 0 | 0 | 0 | For |
| MERGER FUND | 189,620 | 0 | 0 | 0 | For |
| New York Life | 167,391 | 0 | 0 | 0 | For |
| ARBITRAGE FUNDS | 150,311 | 0 | 0 | 0 | For |
| NEXPOINT FUNDS I | 148,800 | 0 | 0 | 0 | For |
| FINANCIAL INVESTORS TRUST | 135,440 | 0 | 0 | 0 | For |
| Investment Managers Series Trust II | 99,879 | 0 | 0 | 0 | For |
| State Street | 0 | 96,154 | 0 | 0 | Against |
| Principal | 93,645 | 0 | 0 | 0 | For |
| Equitable | 55,180 | 0 | 32,500 | 0 | Mixed |
| Columbia Threadneedle | 80,997 | 0 | 0 | 0 | For |
| TIAA | 79,284 | 0 | 0 | 0 | For |
| Goldman Sachs | 53,965 | 0 | 0 | 0 | For |
| Jackson National | 52,392 | 0 | 0 | 0 | For |
| American Century | 51,846 | 0 | 0 | 0 | For |
| JPMorgan | 50,873 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 49,408 | 0 | 0 | 0 | For |
| ALGER INSTITUTIONAL FUNDS | 38,692 | 0 | 0 | 0 | For |
| Aberdeen | 34,250 | 0 | 0 | 0 | For |
Fund voting reports, all 74 managers: 6,990,032 for, 705,049 against, 32,500 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| TimesSquare Capital Management, LLC | 274,468 | 0 | 0 | 0 | For |
Institutional-manager reports, all 1 managers: 274,468 for.
Combines 13 wordings of this item as funds reported it.
68% Approved · of votes cast
Description as filed by funds: To approve, on an advisory, non- binding basis, compensation that will or may be paid or become payable to Reata's named executive officers in connection with the Merger contemplated by the Merger Agreement.
REATA PHARMACEUTICALS INC.’s own tally for this item (“2. Proposal No. 2 - The Advisory Compensation Proposal: To approve, on an advisory, non-binding basis, compensation that will or may be paid or become payable to Reata's named executive officers in connection with the Me”): 28,023,999 for, 12,977,053 against — passed, per its Form 8-K filed September 21, 2023 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Advisory Compensation Proposal was approved by the requisite vote as follows:”
Support: 68% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 0 | 2,777,206 | 0 | 0 | Against |
| BlackRock | 0 | 1,131,027 | 0 | 0 | Against |
| Fidelity | 0 | 624,911 | 0 | 0 | Against |
| Invesco | 0 | 400,289 | 0 | 0 | Against |
| Charles Schwab | 0 | 217,992 | 0 | 0 | Against |
| JANUS INVESTMENT FUND | 193,478 | 0 | 0 | 0 | For |
| Voya | 0 | 0 | 191,544 | 0 | Abstain |
| MERGER FUND | 189,620 | 0 | 0 | 0 | For |
| New York Life | 0 | 167,391 | 0 | 0 | Against |
| ARBITRAGE FUNDS | 150,311 | 0 | 0 | 0 | For |
| NEXPOINT FUNDS I | 0 | 148,800 | 0 | 0 | Against |
| FINANCIAL INVESTORS TRUST | 135,440 | 0 | 0 | 0 | For |
| Investment Managers Series Trust II | 99,179 | 700 | 0 | 0 | For |
| State Street | 0 | 96,154 | 0 | 0 | Against |
| Principal | 90,078 | 3,567 | 0 | 0 | For |
| Equitable | 9,000 | 78,680 | 0 | 0 | Mixed |
| Columbia Threadneedle | 0 | 80,997 | 0 | 0 | Against |
| TIAA | 0 | 79,284 | 0 | 0 | Against |
| Goldman Sachs | 0 | 53,965 | 0 | 0 | Against |
| Jackson National | 11,541 | 40,851 | 0 | 0 | Mixed |
| American Century | 0 | 51,846 | 0 | 0 | Against |
| JPMorgan | 0 | 50,873 | 0 | 0 | Against |
| QUANTITATIVE MASTER SERIES LLC | 0 | 49,408 | 0 | 0 | Against |
| ALGER INSTITUTIONAL FUNDS | 0 | 38,692 | 0 | 0 | Against |
| Aberdeen | 34,250 | 0 | 0 | 0 | For |
Fund voting reports, all 74 managers: 1,057,363 for, 6,478,674 against, 191,544 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| CPMG Inc | 4,589,758 | 0 | 0 | 0 | For |
| Man Group plc | 0 | 1,596,120 | 0 | 0 | Against |
| First Light Asset Management, LLC | 1,082,646 | 0 | 0 | 0 | For |
| FARALLON CAPITAL MANAGEMENT LLC | 1,061,032 | 0 | 0 | 0 | For |
| BlackRock | 8,903 | 605,494 | 0 | 0 | Against |
| GEODE CAPITAL MANAGEMENT, LLC | 0 | 607,391 | 0 | 0 | Against |
| Fidelity | 0 | 589,456 | 0 | 0 | Against |
| State Street | 0 | 476,806 | 0 | 0 | Against |
| Blackstone Inc. | 340,793 | 0 | 0 | 0 | For |
| Invesco | 0 | 312,871 | 0 | 0 | Against |
| BALYASNY ASSET MANAGEMENT L.P. | 0 | 308,989 | 0 | 0 | Against |
| TimesSquare Capital Management, LLC | 274,468 | 0 | 0 | 0 | For |
| Magnetar Financial LLC | 0 | 250,421 | 0 | 0 | Against |
| HBK INVESTMENTS L P | 0 | 245,614 | 0 | 0 | Against |
| MPM BioImpact LLC | 233,691 | 0 | 0 | 0 | For |
| EMERALD MUTUAL FUND ADVISERS TRUST | 232,277 | 0 | 0 | 0 | For |
| Voya | 0 | 29,980 | 191,544 | 0 | Mixed |
| Charles Schwab | 0 | 217,992 | 0 | 0 | Against |
| WATER ISLAND CAPITAL LLC | 215,024 | 0 | 0 | 0 | For |
| Sofinnova Investments, Inc. | 141,598 | 48,668 | 0 | 0 | Mixed |
| MELLON INVESTMENTS Corp | 0 | 169,253 | 0 | 0 | Against |
| UBS | 0 | 167,738 | 0 | 0 | Against |
| GLAZER CAPITAL, LLC | 0 | 164,337 | 0 | 0 | Against |
| EMERALD ADVISERS, LLC | 153,443 | 0 | 0 | 0 | For |
| Wellington | 0 | 144,068 | 0 | 0 | Against |
Institutional-manager reports, all 186 managers: 9,100,658 for, 7,849,698 against, 233,643 abstained, 29,810 not voted, 1,632 unknown, 5 1 year. Showing the 25 largest; every one is in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
0% of fund votes cast · no official result
The 7 asset managers below reported 1,142,909 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 0 | 1,031,125 | 0 | 0 | Against |
| JPMorgan | 0 | 77,107 | 0 | 0 | Against |
| Walleye Capital LLC | 0 | 33,682 | 0 | 0 | Against |
| Walleye Trading LLC | 0 | 671 | 0 | 0 | Against |
| Desjardins Global Asset Management Inc. | 0 | 291 | 0 | 0 | Against |
| TD ASSET MANAGEMENT INC | 0 | 33 | 0 | 0 | Against |
| Taconic Capital Advisors LP | 0 | 0 | 0 | 0 | -- |
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 37,311,872 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 7.44% |
| 2 | BlackRock | 3.03% |
| 3 | Fidelity | 1.67% |
| 4 | Invesco | 1.07% |
| 5 | Charles Schwab | 0.58% |
| 6 | JANUS INVESTMENT FUND | 0.52% |
| 7 | Voya | 0.51% |
| 8 | MERGER FUND | 0.51% |
| 9 | New York Life | 0.45% |
| 10 | ARBITRAGE FUNDS | 0.40% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | CPMG Inc | 12.30% |
| 2 | Man Group plc | 4.28% |
| 3 | First Light Asset Management, LLC | 2.90% |
| 4 | FARALLON CAPITAL MANAGEMENT LLC | 2.84% |
| 5 | BlackRock | 1.65% |
| 6 | GEODE CAPITAL MANAGEMENT, LLC | 1.63% |
| 7 | Fidelity | 1.58% |
| 8 | State Street | 1.28% |
| 9 | Blackstone Inc. | 0.91% |
| 10 | Invesco | 0.84% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| Norges Bank | 165,482 | 0.44% | Form 13F, quarter ended March 31, 2024 |
Percentages above are of 37,311,872 shares outstanding, as reported by REATA PHARMACEUTICALS INC. on its Form 10-Q dated June 30, 2023 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At REATA PHARMACEUTICALS INC.'s shareholder meeting held September 21, 2023, in the 2023-2024 proxy season, 263 asset managers reported votes on at least one item in their SEC Form N-PX filings, covering 1,036 separate fund positions. Their filings are grouped here into 4 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on an advisory, non- binding basis, compensation that will or may be paid or become… — REATA PHARMACEUTICALS INC.'s filing reports the proposal as approved, with 68% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: REATA PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on September 21, 2023.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from REATA PHARMACEUTICALS INC.’s 10-Q dated June 30, 2023. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
REATA PHARMACEUTICALS INC. proxy season coverage: 2023-2024 (this page).
Proxy Votes Now, “REATA PHARMACEUTICALS INC. 2023 Special Meeting (2023-2024 season)”, https://proxyvotesnow.com/company/reata-pharmaceuticals-inc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.